Nanomaterials comprising a biodegradable feature

Patent metadata

Field	Value
Publication number	US-12268753-B2
Application number	US-202217579150-A
Country	US
Kind code	B2
Filing date	Jan 19, 2022
Priority date	Jan 20, 2021
Publication date	Apr 8, 2025
Grant date	Apr 8, 2025

Abstract

The present disclosure describes compositions, preparations, nanoparticles (such as lipid nanoparticles), and/or nanomaterials and methods of their use.

First claim

We claim:

1. A compound of Formula (IIIA):

or a pharmaceutically acceptable salt thereof, wherein:
L 2 is a covalent bond, an optionally substituted bivalent saturated or unsaturated, straight or branched C 1 -C 12 hydrocarbon chain, or

Cy A is an optionally substituted ring selected from phenylene and 3- to 7-membered saturated or partially unsaturated carbocyclene;
each m is independently 0, 1, or 2;
R 1 is a saturated, branched C 3 -C 20 hydrocarbon chain;
each L 4 is independently a bivalent saturated or unsaturated, straight or branched C 1 -C 6 hydrocarbon chain;
each A 1 and A 2 is independently C 2 -C 20 alkenyl;
X 1 is a covalent bond, —O—, or —NR—;
—X 2 —X 3 is selected from:

2. The compound of claim 1 , wherein the compound of Formula (IIIA) is a compound of Formula (VI):

or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, 3 or 4.

3. The compound of claim 1 , wherein the compound of Formula (IIIA) is a compound of Formula (VIA):

or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, 3 or 4.

4. The compound of claim 1 , wherein R′ is selected from:

5. The compound of claim 1 , wherein each of A1 and A2 is independently selected from:

6. The compound of claim 1 , wherein the compound is selected from

or a pharmaceutically acceptable salt thereof.

7. A lipid nanoparticle (LNP) preparation comprising the compound according to claim 1 .

8. A pharmaceutical composition comprising the LNP preparation of claim 7 and a pharmaceutically acceptable excipient.

9. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

10. A lipid nanoparticle (LNP) preparation comprising the compound according to claim 9 .

11. A pharmaceutical composition comprising the LNP preparation of claim 10 and a pharmaceutically acceptable excipient.

12. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

13. A lipid nanoparticle (LNP) preparation comprising the compound according to claim 12 .

14. A pharmaceutical composition comprising the LNP preparation of claim 13 and a pharmaceutically acceptable excipient.

Assignees

• Beam Therapeutics Inc

Inventors

• Shehata Mina Fawzy
• Patwardhan Neeraj Narendra
• Hamilton Gregory Lawrence
• Sago Cory Dane
• Chhabra Milloni Balwantkumar

Classifications

• C07D211/22 Primary

  by oxygen atoms · CPC title

• A61K31/711

  Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links · CPC title

• A61K31/7105 Primary

  Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title

• C07C219/16

  having at least one of the hydroxy groups esterified by an inorganic acid or a derivative thereof · CPC title